Spyre Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
SYRE$103.86+7.5%Stored close · as of Nov 6, 2026
Contents
Item 7.
SPYRE THERAPEUTICS, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
|---|---|
| Audited Consolidated Financial Statements | |
| Report of Independent Registered Public Accounting Firm (ID 185 KPMG LLP) | 110 |
| Report of Independent Registered Public Accounting Firm (ID 238 Pricewaterhouse Coopers LLC) | 112 |
| Consolidated Balance Sheets | 113 |
| Consolidated Statements of Operations | 114 |
| Consolidated Statements of Comprehensive Loss | 115 |
| Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity | 116 |
| Consolidated Statements of Cash Flows | 118 |
| Notes to Consolidated Financial Statements | 120 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.